Vanda Pharmaceuticals said the European Medicines Agency’s Committee for Orphan Medicinal Products issued a positive opinion recommending orphan drug designation for Imsidolimab, its investigational monoclonal antibody. The designation supports the program’s regulatory pathway for the targeted indication, which is a constructive (though not yet approvals-level) milestone for the stock.
Vanda Pharmaceuticals said the European Medicines Agency’s Committee for Orphan Medicinal Products issued a positive opinion recommending orphan drug designation for Imsidolimab, its investigational monoclonal antibody. The designation supports the program’s regulatory pathway for the targeted indication, which is a constructive (though not yet approvals-level) milestone for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
